#IRD

Institute for Ophthalmic Research in Tübingen

@eye-tuebingen.bsky.social

3 days ago

IOR Tübingen @blanka-g.bsky.social & Prof Ueffing are invited by the patient organization Cure VCP Disease, for a talk on “Targeting VCP in Inherited Retinal Dystrophies” on March 26 at 5:00 PM (Berlin/Rome time).
Further details www.eye-tuebingen.de?tx_news_pi1%...
@unituebingen.bsky.social #IRD

StockTitan

@stocktitan.net

4 days ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep

#IRD Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

www.stocktitan.net/news/IRD/opus-genetics-a...

StockTitan

@stocktitan.net

2 weeks ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting Opus Genetics (Nasdaq: IRD) reported 3-month sentinel participant data for its Phase 1/2 OPGx-BEST1 gene therapy for BEST1-related retinal disease.The treated 63-year-old participant showed no ocular inflammation, no treatment-related adverse events, and no dose-limiting toxicities. Efficacy signals included a 12-letter BCVA gain and 23% central subfield thickness (CST) reduction at three months. Full Cohort 1 data expected mid-year 2026.

#IRD Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

www.stocktitan.net/news/IRD/opus-genetics-a...

scientifyRESEARCH

@scientifyresearch.org

2 weeks ago

Why did it take years for Mira to get a diagnosis?

Meet Dr. Mariam Ibrahim, participant in the SciComm Award: Rare Disease Advances.

In her essay, she explores inherited retinal dystrophy.

Read: www.scientifyresearch.org/blog/gene-vi...

#RareDisease #ScienceCommunication #IRD

Bruno Renkin

@bruno-renkin.bsky.social

2 weeks ago

Une nouvelle technique permet (enfin) de révéler les fonds marins côtiers du monde entier Une nouvelle méthode permet, en utilisant des satellites de mesurer les caractéristiques des vagues afin d’estimer la profondeur et donc de mieux connaître les fonds marins à l’échelle du monde entier...

Sécurité de navigation, risques d’érosion côtière et de submersion, économie bleue… autant de raisons de cartographier les fonds marins
#Sentinel-2 #Copernicus #ESA #CNES #IRD, #Shom #S2Shores
theconversation.com/une-nouvelle...

IRD

@ird-fr.bsky.social

1 month ago

🔬🌍 Concours chercheuses-chercheurs #IRD 2026 ouverts
37 postes pour s’engager dans une recherche internationale, partenariale et porteuse de sens.
Climat, biodiversité, santé, sociétés, transitions…
📅 Candidatures jusqu’au 10/03/2026
🔗 www.ird.fr/concours-che...

@enseignementsup-recherche.gouv.fr

StockTitan

@stocktitan.net

1 month ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa Opus Genetics (Nasdaq: IRD) launched a clinical trial for OPGx-MERTK, an AAV-based gene therapy for MERTK-related retinitis pigmentosa, with funding from Abu Dhabi’s Healthcare Research and Innovation Fund.Cleveland Clinic Abu Dhabi will serve as the clinical site and clinical development activities are expected to commence in 2026. The program targets a disease affecting an estimated 60,000 patients worldwide and addresses an area with no approved treatments.

#IRD Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

www.stocktitan.net/news/IRD/opus-genetics-l...

I-Trop @ird-fr.bsky.social Bioinformatics platform

@i-trop.bsky.social

1 month ago

Annuellement depuis 2019, notre réseau d’admins sys d’Afrique de l’Ouest piloté par celui du plateau i-Trop #IRD a organisé sa formation #HPC du 8-12déc/25 à Abidjan. Cette édition s’est axée sur l’accueil de nouveaux membres et le partage de bases pour le déploiement et l’exploitation de clusters.

LUMEN

@lumen-eu.bsky.social

2 months ago

🙌 New #LUMENVoices! 🙌
In this edition, Alessandro Rizzo shares insights from #IRD and its role within #LUMEN.. 🔗 Read the full interview: lumenproject.eu/lumen-voices...

IRD

@ird-fr.bsky.social

2 months ago

🤝 @cnes.fr, #IRD, laboratoire LEGOS, SHOM

StockTitan

@stocktitan.net

2 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts Opus Genetics (Nasdaq: IRD) reviewed 2025 progress and outlined 2026 catalysts across its ophthalmic gene therapy pipeline. Key near-term milestones include 3-month cohort data from the Phase 1/2 BEST1 trial expected mid-2026, initiation of pivotal Phase 3 dosing for LCA5 in the second half of 2026 after positive Phase 1/2 results, and an sNDA submission for a partnered presbyopia treatment with a regulatory decision anticipated by end of 2026. The company reported cash and cash equivalents of $30.8M as of Sept 30, 2025 and raised ~$23.0M in a subsequent registered direct offering, giving a cash runway into the second half of 2027 based on current plans. Multiple programs may qualify for Rare Pediatric Disease designation and other expedited pathways.

#IRD Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

www.stocktitan.net/news/IRD/opus-genetics-h...

ASX Market Sensitive Announcements

@asxmktsensitive.bsky.social

2 months ago

Iron Road ( #IRD ) has released " Revera Energy Cape Hardy Option to Purchase Update " on Fri 02 Jan at 09:12 AEST #Australia #ltd #ASX #price #Hydrogen

Christine Siddoway

@iphigenesdream.bsky.social

2 months ago

I still can scarcely believe, as a land geologist, that I experienced was able to sail on #TheJR for #IODP379 deep sea drilling in outer #AmundsenSea. (And a lucky thing, too -- because there was a quantity of #IRD ice rafted ROCK debris that glaciers carved out of the continental bedrock!)

Société Française de BioInformatique

@sfbi.fr

2 months ago

Photo de groupe lors des RABIAS

📍 Du 15 au 17 décembre 2025, une délégation de la #SFBI, de l’ #IFB (ELIXIR-FR) et de l’Université de Montpellier a été invitée au lancement du Réseau ouest Africain des Bioinformaticiens et Administrateurs de Systèmes (#RABIAS), organisé par #WAVE et l’ #IRD

ℹ️ www.sfbi.fr/blog/article...

Paula Lindner

@drpaulalindner.bsky.social

2 months ago

📰𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗼𝘂𝘁: 𝗖𝗶𝗿𝗰𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗹𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗻 – 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗮𝘀𝘀𝗲𝘀𝘀 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻. Why is circulating hashtag#calprotectin gaining so much attention in rheumatology? In our latest GCAL® newsletter, we share insights from recent conferences, new literature, and real-world clinical experience showing how calprotectin is shaping inflammation monitoring in Inflammatory Rheumatic Diseases hashtag#IRDs

Last newsletter of the year.

𝗖𝗶𝗿𝗰𝘂𝗹𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗹𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗻 – 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗮𝘀𝘀𝗲𝘀𝘀 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻.
#Calprotectin #RheumSky #IRD

www.linkedin.com/posts/gentia...

StockTitan

@stocktitan.net

3 months ago

#IRD Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

www.stocktitan.net/news/IRD/opus-genetics-a...

Christine Siddoway

@iphigenesdream.bsky.social

3 months ago

How did I miss this post, @tomarney.com ?? That is one mighty fine title page!! #AntarcticaDay #AmundsenSea #IRD #SouthernOcean #subglacialBedrock #WAIS #WestAntarcticIceSheet 🙌

Richard ☠️ Monvoisin

@richardmonvoisin.mastodon.social.ap.brid.gy

3 months ago

Il semble que ce soit en vendant à Daniel Rolander, un étudiant de Linné, la formule de sa tisane (fruit semble-t-il d'une confidence d’un Saamaka, un esclave marron en fuite) qu’il pu acheter sa liberté, et même devenir propriétaire d’une plantation, avec ses propres esclaves ! Misère.

240 ans […]

StockTitan

@stocktitan.net

4 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease Opus Genetics (Nasdaq: IRD) announced dosing of the first participant in the OPGx-BEST1 Phase 1/2 gene therapy trial for Best disease on Nov 13, 2025. The one-time subretinal injection therapy targets BEST1-mutant retinal pigment epithelium cells. The trial is led by Dr. Mark Pennesi with surgical teams at Retina Consultants of Texas. Initial clinical data are expected in Q1 2026.

#IRD Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

www.stocktitan.net/news/IRD/opus-genetics-a...

StockTitan

@stocktitan.net

4 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update Opus Genetics (Nasdaq: IRD) reported Q3 2025 results and a corporate update on Nov 12, 2025. Key clinical highlights include positive 3-month pediatric and 18-month adult data from the OPGx-LCA5 Phase 1/2 trial and a successful FDA RMAT meeting that could enable an accelerated pathway. The company opened enrollment for OPGx-BEST1 and plans dosing for a Phase 3 LCA5 portion in H2 2026 with topline ~one year later.Financially, cash was $30.8M at Sept 30, 2025 plus ~$23.0M raised post-quarter (cash >$50M) expected to fund operations into H2 2027; Q3 revenue was $3.1M and net loss was $17.5M (Q3 2025).

#IRD Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

www.stocktitan.net/news/IRD/opus-genetics-a...

StockTitan

@stocktitan.net

4 months ago

Opus Genetics Announces $23 Million Registered Direct Offering Opus Genetics (Nasdaq: IRD) announced a registered direct offering to raise approximately $23 million in gross proceeds, led by Perceptive Advisors and Balyasny Asset Management with participation from Nantahala Capital.The company will sell 3,827,751 common shares at $2.09 per share and issue pre-funded warrants to purchase up to 7,177,033 shares at $2.0899 each (exercise price $0.0001), immediately exercisable. Expected close date is November 7, 2025. Proceeds are targeted to advance the LCA5 and BEST-1 gene therapy programs and for working capital. Based on current plans, cash is expected to fund operations into the second half of 2027, excluding any proceeds from callable warrants or milestone payments.

#IRD Opus Genetics Announces $23 Million Registered Direct Offering

www.stocktitan.net/news/IRD/opus-genetics-a...

StockTitan

@stocktitan.net

4 months ago

Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness Opus Genetics (Nasdaq: IRD) was featured on Good Morning America on Nov 3, 2025 for its investigational gene therapy OPGx-LCA5 targeting LCA5-related inherited retinal disease. The segment highlighted participant Lindsey Rambo and described the therapy's approach of delivering a functional LCA5 gene to retinal cells to restore photoreceptor function and partial vision.The story coincides with ongoing Phase 1/2 trials, multiple active clinical programs for LCA5 and BEST1, a newly activated site at the Retina Foundation of the Southwest, and support from RD Fund and Foundation Fighting Blindness.

#IRD Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness

www.stocktitan.net/news/IRD/opus-genetics-f...

Tāne

@daylightdawn.bsky.social

4 months ago

"My brother, my wife and I are in the top echelon of taxpayers in New Zealand," he said. "We use two leading accountancy companies to manage our returns and play the game according to the rules and always have done … in my mind it is tantamount to legalised theft."
#IRD
#AoNZpol

Patrick

@siucraym.mastodon.cloud.ap.brid.gy

4 months ago

Today is International #Repair Day! 🛠️🪛
https://en.wikipedia.org/wiki/International_Repair_Day
https://openrepair.org/international-repair-day
https://www.daysoftheyear.com/days/repair-day
#InternationalRepairDay #IRD #InternationalRepairDay2025 #IRD2025 #RightToRepair

Valérie Verdier

@valerieverdier.bsky.social

5 months ago

#BiennaleEuroAfrica2025 Riches échanges hier avec Patrick Caron sur la transformation du modèle @CGIAR
Vers une meilleure intégration des chercheurs, un élargissement au Sud, en lien avec les partenariats #IRD, pour une mobilisation des grands bailleurs autour des enjeux globaux 🌍

StockTitan

@stocktitan.net

5 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses observed out to 18 months in adult participants Expected FDA Meeting in Q4 2025 Management to Host

#IRD Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

www.stocktitan.net/news/IRD/opus-genetics-r...

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks with improving money flow, Thu Sept 25th - #SLI #LCTX #XMTR #VECO #TLS #SEPN #PPSI #ONDS #MASS #IRD #EVAX #IBO #DXLG #CLRB #BTOC #AENT #VOC #SBR #OWLT #INVX #DQ #AMBC - More: crystalequityresearch.com/leading-indi... - #smallcap

ASX Market Sensitive Announcements

@asxmktsensitive.bsky.social

6 months ago

Iron Road ( #IRD ) has released " Revera Cape Hardy Land Purchase Option Update " on Mon 01 Sep at 08:48 AEST #Australia #ltd #ASX #Hydrogen #rise